MA35237B1 - Anticorps neutralisant le récepteur de la prolactine mat3 et usage thérapeutique associé - Google Patents

Anticorps neutralisant le récepteur de la prolactine mat3 et usage thérapeutique associé

Info

Publication number
MA35237B1
MA35237B1 MA36513A MA36513A MA35237B1 MA 35237 B1 MA35237 B1 MA 35237B1 MA 36513 A MA36513 A MA 36513A MA 36513 A MA36513 A MA 36513A MA 35237 B1 MA35237 B1 MA 35237B1
Authority
MA
Morocco
Prior art keywords
mat3
prolactin
receptor
prolactin receptor
benign
Prior art date
Application number
MA36513A
Other languages
English (en)
Inventor
Axel Harrenga
Christiane Otto
Christoph Freiberg
Mark Trautwein
Andreas Wilmen
Simone Greven
Lars Linden
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Publication of MA35237B1 publication Critical patent/MA35237B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

L'invention concerne l'anticorps neutralisant le récepteur de la prolactine mat3, ainsi que des fragments de liaison à l'antigène, des compositions pharmaceutiques les contenant et leur utilisation de le traitement ou la prévention d'indications et de troubles bénins induits par le récepteur de la prolactine, tels que l'endométriose, l'adénomyose, la contraception féminine non hormonale, l'affection bénigne des seins et la mastodynie, l'inhibition de la lactation, l'hyperplasie bénigne de la prostate, les fibromyomes, la perte de cheveux hyperprolactinémique et normoprolactinémique, ainsi qu'un cotraitement en hormonothérapie combinée destinée à inhiber la prolifération de cellules épithéliales mammaires et dans le traitement et la prévention du cancer du sein résistant aux anti-oestrogènes. L'anticorps selon l'invention bloque la signalisation induite par le récepteur de la prolactine.
MA36513A 2011-06-03 2013-12-02 Anticorps neutralisant le récepteur de la prolactine mat3 et usage thérapeutique associé MA35237B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11168644A EP2530089A1 (fr) 2011-06-03 2011-06-03 Anticorps neutralisant Mat3 contre le récepteur de prolactine et son utilisation thérapeutique
PCT/EP2012/060078 WO2012163932A1 (fr) 2011-06-03 2012-05-31 Anticorps neutralisant le récepteur de la prolactine mat3 et usage thérapeutique associé

Publications (1)

Publication Number Publication Date
MA35237B1 true MA35237B1 (fr) 2014-07-03

Family

ID=46331236

Family Applications (1)

Application Number Title Priority Date Filing Date
MA36513A MA35237B1 (fr) 2011-06-03 2013-12-02 Anticorps neutralisant le récepteur de la prolactine mat3 et usage thérapeutique associé

Country Status (37)

Country Link
US (2) US9353186B2 (fr)
EP (2) EP2530089A1 (fr)
JP (1) JP5859641B2 (fr)
KR (1) KR101920521B1 (fr)
CN (1) CN103764679B (fr)
AP (1) AP2013007266A0 (fr)
AR (1) AR086631A1 (fr)
AU (1) AU2012264765B2 (fr)
BR (1) BR112013030995B1 (fr)
CA (1) CA2837736C (fr)
CL (1) CL2013003459A1 (fr)
CO (1) CO6852025A2 (fr)
CR (1) CR20130632A (fr)
CU (1) CU20130163A7 (fr)
CY (1) CY1117660T1 (fr)
DK (1) DK2714740T3 (fr)
DO (1) DOP2013000285A (fr)
EA (1) EA029316B1 (fr)
EC (1) ECSP13013063A (fr)
ES (1) ES2572215T3 (fr)
HR (1) HRP20160506T1 (fr)
HU (1) HUE028775T2 (fr)
IL (1) IL229504B (fr)
MA (1) MA35237B1 (fr)
ME (1) ME02659B (fr)
MX (1) MX343683B (fr)
PE (1) PE20141158A1 (fr)
PH (1) PH12013502494A1 (fr)
PL (1) PL2714740T3 (fr)
RS (1) RS54727B1 (fr)
SG (1) SG195060A1 (fr)
SI (1) SI2714740T1 (fr)
TN (1) TN2013000501A1 (fr)
TW (1) TWI548649B (fr)
UY (1) UY34116A (fr)
WO (1) WO2012163932A1 (fr)
ZA (1) ZA201309683B (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ631565A (en) 2012-03-14 2016-07-29 Regeneron Pharma Multispecific antigen-binding molecules and uses thereof
EP2935331B1 (fr) 2012-12-24 2018-02-28 AbbVie Inc. Protéines de liaison au récepteur de la prolactine et utilisations de celles-ci
US9545451B2 (en) 2013-08-21 2017-01-17 Regeneron Pharmaceuticals, Inc. Anti-PRLR antibodies and methods for killing PRLR-expressing cells
TWI641620B (zh) 2013-08-21 2018-11-21 再生元醫藥公司 抗－ｐｒｌｒ抗體及其用途
MY189159A (en) 2015-07-06 2022-01-29 Regeneron Pharma Multispecific antigen-binding molecules and uses thereof
WO2017190079A1 (fr) 2016-04-28 2017-11-02 Regeneron Pharmaceuticals, Inc. Procédés de production de molécules multispécifiques se liant à l'antigène
EP3548514A1 (fr) 2016-11-29 2019-10-09 Regeneron Pharmaceuticals, Inc. Méthodes de traitement du cancer du sein positif à prlr
TW201836647A (zh) 2017-04-06 2018-10-16 美商艾伯維有限公司 抗－ｐｒｌｒ抗體藥物軛合物（ａｄｃ）及其用途
AU2018300687A1 (en) 2017-07-10 2019-12-19 Bayer Pharma Aktiengesellschaft Prolactin receptor antibody for male and female pattern hair loss
PT3587445T (pt) * 2017-08-10 2024-03-14 Grifols Diagnostic Solutions Inc Um marcador de oligomerização compreendendo uma região fc de imunoglobulina e um domínio poli-his
CN112040985A (zh) 2018-02-07 2020-12-04 瑞泽恩制药公司 用于递送治疗性蛋白质的方法和组合物
AR124681A1 (es) 2021-01-20 2023-04-26 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr
EP4428150A1 (fr) 2023-03-07 2024-09-11 Peptide Logic LLC Anticorps ou fragment de liaison à l'antigène de celui-ci
CN116655791B (zh) * 2023-05-06 2023-11-07 浙江触奇生物科技有限公司 一种抗泌乳素受体的纳米抗体、重组载体、重组菌和应用
CN120388750B (zh) * 2025-04-15 2025-12-09 绵阳市妇幼保健院(绵阳市儿童医院) 一种子宫内膜异位症患者哺乳期复查随访数据处理系统

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4657760A (en) 1979-03-20 1987-04-14 Ortho Pharmaceutical Corporation Methods and compositions using monoclonal antibody to human T cells
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
JP4157160B2 (ja) 1991-12-13 2008-09-24 ゾーマ テクノロジー リミテッド 改変抗体可変領域の調製のための方法
ATE219517T1 (de) 1995-08-18 2002-07-15 Morphosys Ag Protein-/(poly)peptidbibliotheken
GB9701425D0 (en) 1997-01-24 1997-03-12 Bioinvent Int Ab A method for in vitro molecular evolution of protein function
WO2003008583A2 (fr) 2001-03-02 2003-01-30 Sagres Discovery Nouvelles compositions et methodes relatives au cancer
AU2002322280A1 (en) 2001-06-21 2003-01-21 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
EP1325930A1 (fr) * 2002-01-08 2003-07-09 Institut National De La Sante Et De La Recherche Medicale (Inserm) Variants de Prolactin de mammifère
EP2083088A3 (fr) 2005-04-07 2009-10-14 Novartis Vaccines and Diagnostics, Inc. Gènes associés au cancer
US7422899B2 (en) 2005-10-05 2008-09-09 Biogen Idec Ma Inc. Antibodies to the human prolactin receptor
EP3018144A1 (fr) * 2006-08-18 2016-05-11 XOMA Technology Ltd. Anticorps prlr spécifique et ses utilisations
EP2332995A1 (fr) * 2009-12-10 2011-06-15 Bayer Schering Pharma Aktiengesellschaft Neutralisation d'anticorps récepteurs de prolactine et leur utilisation thérapeutique

Also Published As

Publication number Publication date
AU2012264765B2 (en) 2016-07-28
EA201301356A1 (ru) 2014-09-30
UY34116A (es) 2013-01-03
KR20140036275A (ko) 2014-03-25
PH12013502494A1 (en) 2014-01-20
BR112013030995B1 (pt) 2021-11-09
EP2714740A1 (fr) 2014-04-09
ES2572215T3 (es) 2016-05-30
CN103764679A (zh) 2014-04-30
CO6852025A2 (es) 2014-01-30
JP2014522239A (ja) 2014-09-04
CN103764679B (zh) 2016-05-04
HRP20160506T1 (hr) 2016-06-17
TN2013000501A1 (en) 2015-03-30
DOP2013000285A (es) 2014-03-16
EP2530089A1 (fr) 2012-12-05
PE20141158A1 (es) 2014-09-26
JP5859641B2 (ja) 2016-02-10
SG195060A1 (en) 2013-12-30
TW201302798A (zh) 2013-01-16
SI2714740T1 (sl) 2016-06-30
US9777063B2 (en) 2017-10-03
EP2714740B1 (fr) 2016-03-30
US9353186B2 (en) 2016-05-31
ZA201309683B (en) 2016-08-31
AR086631A1 (es) 2014-01-08
CL2013003459A1 (es) 2014-08-08
RS54727B1 (sr) 2016-10-31
MX343683B (es) 2016-11-17
PL2714740T3 (pl) 2016-08-31
CU20130163A7 (es) 2014-04-24
IL229504B (en) 2018-10-31
WO2012163932A1 (fr) 2012-12-06
IL229504A0 (en) 2014-01-30
AU2012264765A1 (en) 2013-12-19
CR20130632A (es) 2014-02-04
HK1195081A1 (zh) 2014-10-31
CY1117660T1 (el) 2017-05-17
BR112013030995A2 (pt) 2016-11-22
MX2013014174A (es) 2014-11-13
KR101920521B1 (ko) 2018-11-21
CA2837736C (fr) 2018-11-20
EA029316B1 (ru) 2018-03-30
US20160319029A1 (en) 2016-11-03
ME02659B (fr) 2017-06-20
NZ618316A (en) 2016-01-29
HUE028775T2 (en) 2017-01-30
AP2013007266A0 (en) 2013-11-30
TWI548649B (zh) 2016-09-11
CA2837736A1 (fr) 2012-12-06
US20140141003A1 (en) 2014-05-22
ECSP13013063A (es) 2014-01-31
DK2714740T3 (da) 2016-05-30

Similar Documents

Publication Publication Date Title
CY1118407T1 (el) Αντισωματα εξουδετερωσης υποδοχεα προλακτινης και θεραπευτικη χρηση αυτων
MD20150035A2 (ro) Inhibitori de tirozinkinaza Bruton
ECSP13013063A (es) El anticuerpo neutralizador del receptor de prolactina mat3 y su uso terapéutico
MA35455B1 (fr) (wo2013045407) dérivés d'estra-1,3,5(10),16-tétraène-3-carboxamide, procédé pour leur fabrication, préparations pharmaceutiques contenant ces substances ainsi que leur utilisation dans la fabrication de médicaments
MA35728B1 (fr) Dérivés de 6,7-dihydro-5h-benzo[7]annulène, leur procédé de préparation, préparations pharmaceutiques les contenant et leur utilisation pour la fabrication de produits pharmaceutiques
PH12013500080A1 (en) Targeted nanoparticles for cancer and other disorders
MA38349A1 (fr) Œstra-1,3,5(10),16-tétraéno-3-carboxamide pour inhiber la 17-bêta-hydroxystéroïde déshydrogénase (akr1c3)
MA37742B1 (fr) Dérivés d'oestra-1,3,5 (10), 16-tétraène substitués en position 3, leurs procédés de préparation, préparations pharmaceutiques les contenant, et leur utilisation pour la fabrication de médicaments
MA30413B1 (fr) Nouvelles compositions pharmaceutiques faiblement dosees contenant du nimesulide, leur preparation et utilisation
MA38190A2 (fr) Inhibiteurs d'autotaxine
MA38253B1 (fr) Compositions comprenant de la vortioxétine et du donépézil
MA39447A1 (fr) (s)-pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine
EA201491614A1 (ru) Способ лечения гинекологических заболеваний
MA39448B1 (fr) (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical
MA39446A1 (fr) Compositions pharmaceutiques pour traiter des maladies infecteuses
MA39188A1 (fr) Composés peptidomimétiques et conjugués anticorps-médicament de ceux-ci